A 51-year-old holding a 1 mg pen and a printout of the 44% nausea figure is afraid of the wrong rung. Semaglutide side effects land hardest during dose escalation, and the labels’ own matched-dose tables show the top rung adding less than the rungs below it. The direct answer in one sentence: the climb makes people sick, the ceiling rarely does, and the handful of reactions that ignore the ladder are the ones that end up in a hospital.
The 44% comes from the Wegovy weight-loss programme in adults. The Ozempic diabetes label, a different programme with different patients, prints 20.3% nausea at 1 mg. We walked the rest of that Wegovy table in Wegovy side effects; this page follows the ladder instead.
Semaglutide Side Effects – The 44% Belongs to One Product, Not the Molecule
The Wegovy prescribing information, version 19, effective 18 June 2026, draws Table 3 from 2,116 adults on 2.4 mg against 1,261 on placebo. Nausea 44% against 16%. Diarrhoea 30% against 16%. Vomiting 24% against 6%. Constipation 24% against 11%.
The Ozempic prescribing information, version 20, effective 1 June 2026, draws Table 1 from 521 adults with type 2 diabetes, mean exposure 32.9 weeks. Nausea 6.1% on placebo, 15.8% at 0.5 mg, 20.3% at 1 mg. Vomiting 2.3, 5 and 9.2. Diarrhoea 1.9, 8.5 and 8.8.
Both labels print the same caution above those tables. Because clinical trials are conducted under widely varying conditions, adverse reaction rates cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The manufacturers put that sentence there to stop the comparison. The comparison is what half the GLP-1 content on page one is built on.
The populations differ as well. The Wegovy safety pool averaged 48 years old, 71% female, 19% with type 2 diabetes. The Ozempic pool averaged 56 years, 55% male, 8.8 years of diabetes and a mean HbA1c of 8.2%. One group chased weight loss. The other managed a disease, and the stomach reports them differently.
Semaglutide Side Effects – What Doubling the Dose Bought
Here the labels hand over something rarer than an incidence table: a matched comparison inside one programme.
Ozempic ran a 40-week trial of 959 patients on 1 mg against 2 mg, both on top of metformin with or without a sulfonylurea. Any gastrointestinal reaction came in at 30.8% at 1 mg and 34% at 2 mg. One extra milligram bought 3.2 percentage points of stomach trouble.
Wegovy’s Table 4 sets 7.2 mg beside 2.4 mg and placebo across two 72-week trials with 1,311 adults exposed at the top dose. Nausea 39% at 7.2 mg against 35% at 2.4 mg and 13% on placebo. Vomiting 22 against 16. Constipation 20 against 19. Hair loss 6 against 3.
Then the line that should end the argument. Permanent discontinuation from adverse reactions ran 5% at 7.2 mg, 5% at 2.4 mg and 2% on placebo. Gastrointestinal discontinuation ran 3%, 3% and 0.3%. Tripling the milligrams did not push more people off the drug.
The weight result for that step, in Study 8, was minus 18.8% at 7.2 mg against minus 15.5% at 2.4 mg. Three point three percentage points of body weight. The higher dose is a trade, and it is not the catastrophe the dose charts imply.
Dysesthesia – The One the Label Admits Rises With the Dose
One reaction does scale, and the Wegovy label says so in flat prose: the incidence of dysesthesia with WEGOVY increased with increasing dosage and drug levels in the blood.
Dysesthesia is the label’s umbrella for odd skin sensations: pins and needles, burning, heightened sensitivity, pain on light touch. At 2.4 mg it ran 6% against 0.3% on placebo. At 7.2 mg it ran 22%. It is also the one listed reaction where the label counts what patients did about it: among 288 people who developed it at 7.2 mg, 2% stopped treatment, 8% interrupted it, and 23% had the dose reduced. Events resolved faster where an action was taken.
A reaction that tracks the milligrams is a reaction a prescriber can bargain with. Drop a rung, keep the patient.
The Escalation Window – Where 73% of the Reports Land
The Wegovy label states that gastrointestinal reactions were most frequently reported during dosage escalation. The Ozempic label says the majority of reports of nausea, vomiting and diarrhoea occurred during dose escalation. Two labels, one behaviour.
The size of it sits in the same paragraph. Across Wegovy adult weight-reduction trials, 73% of treated patients reported a gastrointestinal reaction against 47% on placebo. Severe gastrointestinal reactions ran 4.1% against 0.9%. Stopping treatment over a gastrointestinal reaction ran 4.3% against 0.7%. On Ozempic, severe gastrointestinal reactions ran 0.4% at 0.5 mg and 0.8% at 1 mg, against 0% on placebo.
The manufacturer’s own cardiovascular trial built the escape hatch in. During the 16-week escalation period of Study 1, patients who could not tolerate the recommended escalation dosage could stay at a lower dose level. The company knew where the dropouts would come from.
Most clinic handouts do not carry that sentence. The pen ships with a schedule that assumes a patient keeps climbing on the calendar.
Gallbladder, Pancreas, Kidney, Retina – The Set No Ladder Explains
The serious end of the list does not behave like a dose effect at all.
Cholelithiasis on Wegovy in adults for weight reduction: 1.6% against 0.7% on placebo. Cholecystitis 0.6% against 0.2%. On the 25 mg tablet, gallstones ran 2.5% against 1%. In the adolescent trial, 3.8% against 0%. The label then closes the obvious excuse, noting that substantial or rapid weight loss can raise gallstone risk, yet the incidence of acute gallbladder disease was greater in treated patients than in placebo patients even after accounting for the degree of weight loss. The drug is doing something the kilograms do not explain.
Ozempic’s cholelithiasis figures make the point from the other direction: 1.5% at 0.5 mg and 0.4% at 1 mg, with 0% on placebo. The lower dose produced more gallstones. Nothing about that is ordered by milligrams.
Pancreatitis was confirmed by adjudication in 4 Wegovy-treated patients at 0.2 cases per 100 patient years, against 1 placebo patient at less than 0.1. On Ozempic, 7 treated patients at 0.3 per 100 patient years against 3 comparators at 0.2. Those are rates nobody titrates out of.
Retinal disorders in the Wegovy type 2 diabetes trial ran 6.9% at 2.4 mg, 6.2% at 1 mg and 4.2% on placebo. Resting heart rate rose 1 to 4 beats per minute on Wegovy and 2 to 3 on Ozempic, with 26% of treated Wegovy patients showing a peak rise of 20 beats or more at some visit against 16% on placebo. None of that answers to the dose chart either.
The Missing Sentence – No Duration Anywhere in Either Label
Search both documents for a timeline on nausea and the page comes back empty. The reassuring four-to-eight-weeks figure that fills clinic blogs and video descriptions cites nothing, because there is nothing in the label to cite. It may hold in practice. It is not in the paperwork.
Compounded Semaglutide – A Dose With No Table Behind It
The FDA’s page on unapproved GLP-1 drugs, content current as of 1 October 2026, states that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing. It describes adverse events, some requiring hospitalisation, tied to dosing errors with compounded injectable semaglutide, caused by patients measuring wrong doses and by clinicians miscalculating them.
The failure mode matters here: patients prescribed doses beyond the approved label, which means more product per dose, doses taken more often, or the amount increased more quickly. Faster titration is the behaviour both labels warn against, sold as a shortcut.
As of 31 May 2026 the FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, while noting that state-licensed pharmacies which are not outsourcing facilities need not report, so the count understates. The page also flags semaglutide sodium and semaglutide acetate as different active ingredients from the approved drug, with no lawful basis for compounding use that the agency can identify, and tells patients to discard a multi-dose vial 28 days after first use even where the compounder’s instructions say otherwise.
That is the difference between a labelled product and a vial. One has a table you can argue with. The other has a number a patient reads off a syringe. For the postmarketing side of this molecule, including the esophageal case that followed a restart without titration, see our earlier piece on Ozempic side effects after a break.
Frequently asked questions
Do semaglutide side effects get worse at higher doses?
Mostly not, with one clear exception. The Wegovy label shows nausea rising 4 points and vomiting 6 points between 2.4 mg and 7.2 mg, while permanent discontinuation held at 5% on both. Dysesthesia is the exception: it rose from 6% to 22% across that step, and the label states it increases with dosage and drug levels in the blood.
How common is nausea on semaglutide?
It depends on the product and the trial. Wegovy 2.4 mg recorded 44% nausea against 16% on placebo in adults treated for weight reduction. Ozempic recorded 20.3% at 1 mg against 6.1% on placebo in adults with type 2 diabetes. Both labels warn that rates from separate trials cannot be compared.
How long do semaglutide side effects last?
The labels do not say. They do document that reactions were most frequently reported during dose escalation, and that dysesthesia events resolved faster when the dose was reduced or interrupted.
Is hair loss from semaglutide permanent?
The labels record incidence, not recovery. Wegovy lists hair loss at 3% against 1% on placebo at 2.4 mg, and 6% against 1% at 7.2 mg. Neither label follows patients long enough to answer the permanence question.
What are the serious semaglutide side effects?
The labels name acute pancreatitis, acute gallbladder disease, acute kidney injury from dehydration, diabetic retinopathy complications in type 2 diabetes, severe gastrointestinal reactions and hypersensitivity reactions, plus a boxed warning for thyroid C-cell tumours built on rodent data. Both labels also warn about pulmonary aspiration under anaesthesia.
Can I stay on a lower dose if the side effects are bad?
The Wegovy label’s own cardiovascular trial allowed patients who could not tolerate the recommended escalation to stay at a lower dose level. That remains a prescriber decision made against your history, not a schedule you edit yourself.
Does compounded semaglutide cause the same side effects?
The FDA states that many reported events for compounded products look consistent with the approved versions, while compounding carries no FDA review and reported dosing errors including faster titration. It logged 990 compounded semaglutide reports as of 31 May 2026 and notes the count is likely understated.
Sources: DailyMed, OZEMPIC prescribing information, version 20, effective 1 June 2026. DailyMed, WEGOVY prescribing information, version 19, effective 18 June 2026. FDA, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of 1 October 2026, retrieved 19 October 2026.
Two disclosures: this is a directory for people looking for a clinic, not medical advice, and no page here replaces a prescriber reading your history.